- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04437654
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
The purpose of this study is to investigate the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOAC) in atrial fibrillation patients with intermediate stroke risk (CHA2DS2-VASc score 1 for male, 2 for female).
A. Major safety results include major bleeding and clinically relevant non-major bleeding.
B. Major efficacy results include strokes, systemic embolism and mortality. C. Other results include myocardial infarction, pulmonary embolism, transient ischemic attack, hospitalization, drug compliance, quality of life questionnaire (AFEQT), cognitive function (KDSQ), aging questionnaire(K-Frail) and hand grip strength.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Boyoung Joung
- Phone Number: 82-2-2228-8447
- Email: cby6908@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Severance Cardiovascular Hospital Yonsei University
-
Contact:
- Boyoung Joung
- Phone Number: 82-2-2228-8447
- Email: cby6908@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 19~80 years old
- CHA2DS2-VASc score 1 for male or 2 for female among nonvalvular atrial fibrillation patients
- Patients who agree to register for this study
- Patients who can be observed for the progress after treatment
Exclusion Criteria:
- Severe liver or kidney dysfunction
- Thyroid dysfunction
- Pregnant or breastfeeding women
- Malignant tumors that have not been completely cured
- Severe structural heart disease
- Predicted survival is less than 12 months
- Patients who do not understand the content of the study or disagree with it
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anticoagulation group(Apixaban group)
Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
|
Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
|
No Intervention: Nonanticoagulation group
Standard treatment except anticoagulant for 2 years
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite outcome
Time Frame: Baseline
|
Composite outcome including stroke/systemic embolism, major bleeding, and death
|
Baseline
|
Composite outcome
Time Frame: 1 month
|
Composite outcome including stroke/systemic embolism, major bleeding, and death
|
1 month
|
Composite outcome
Time Frame: 6 months
|
Composite outcome including stroke/systemic embolism, major bleeding, and death
|
6 months
|
Composite outcome
Time Frame: 12 months
|
Composite outcome including stroke/systemic embolism, major bleeding, and death
|
12 months
|
Composite outcome
Time Frame: 18 months
|
Composite outcome including stroke/systemic embolism, major bleeding, and death
|
18 months
|
Composite outcome
Time Frame: 24 months
|
Composite outcome including stroke/systemic embolism, major bleeding, and death
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major bleeding
Time Frame: Baseline
|
The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. |
Baseline
|
Major bleeding
Time Frame: 1 month
|
The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. |
1 month
|
Major bleeding
Time Frame: 6 months
|
The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. |
6 months
|
Major bleeding
Time Frame: 12 months
|
The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. |
12 months
|
Major bleeding
Time Frame: 18 months
|
The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. |
18 months
|
Major bleeding
Time Frame: 24 months
|
The International Society on Thrombosis and Haemostasis (ISTH)/Scientific and Standardization Committee (SSC) definitions and bleeding assessment tool are useful for standardizing the reporting of bleeding symptoms. 1. Fatal bleeding. and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome. and/or 3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. |
24 months
|
Stroke
Time Frame: Baseline
|
)Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms.
Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.
|
Baseline
|
Stroke
Time Frame: 1 month
|
)Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms.
Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.
|
1 month
|
Stroke
Time Frame: 6 months
|
)Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms.
Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.
|
6 months
|
Stroke
Time Frame: 12 months
|
)Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms.
Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.
|
12 months
|
Stroke
Time Frame: 18 months
|
)Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms.
Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.
|
18 months
|
Stroke
Time Frame: 24 months
|
)Ischemic stroke specifically refers to central nervous system infarction (brain, spinal cord, or retinal cell death attributable to ischemia) accompanied by overt symptoms, while silent infarction by definition causes no known symptoms.
Stroke also broadly includes intracerebral hemorrhage and subarachnoid hemorrhage.
|
24 months
|
Systemic embolism
Time Frame: Baseline
|
Systemic embolism refers to emboli in the arterial circulation, and defined by both clinical and objective evidence of sudden loss of end-organ perfusion.
|
Baseline
|
Systemic embolism
Time Frame: 1 month
|
Systemic embolism refers to emboli in the arterial circulation, and defined by both clinical and objective evidence of sudden loss of end-organ perfusion.
|
1 month
|
Systemic embolism
Time Frame: 6 months
|
Systemic embolism refers to emboli in the arterial circulation, and defined by both clinical and objective evidence of sudden loss of end-organ perfusion.
|
6 months
|
Systemic embolism
Time Frame: 12 months
|
Systemic embolism refers to emboli in the arterial circulation, and defined by both clinical and objective evidence of sudden loss of end-organ perfusion.
|
12 months
|
Systemic embolism
Time Frame: 18 months
|
Systemic embolism refers to emboli in the arterial circulation, and defined by both clinical and objective evidence of sudden loss of end-organ perfusion.
|
18 months
|
Systemic embolism
Time Frame: 24 months
|
Systemic embolism refers to emboli in the arterial circulation, and defined by both clinical and objective evidence of sudden loss of end-organ perfusion.
|
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Arrhythmias, Cardiac
- Stroke
- Atrial Fibrillation
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Apixaban
Other Study ID Numbers
- 4-2020-0438
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation Patients With Intermediate Stroke Risk
-
Yonsei UniversityRecruitingAtrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial FibrillationKorea, Republic of
-
Yonsei UniversityNot yet recruitingAtrial Fibrillation/Flutter in Patients With High Risk of StrokeKorea, Republic of
-
Boston Scientific CorporationCompletedPatients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, StrokeIreland, Spain, Germany, Netherlands, France, United Kingdom, Italy, Russian Federation, Portugal, Belgium, Poland, Saudi Arabia, United Arab Emirates
-
Scripps Translational Science InstituteQuest Diagnostics-Nichols InsituteCompletedPatients With Symptoms of Cardiac Arrhythmia at Risk for Atrial FibrillationUnited States
-
Boston Scientific CorporationActive, not recruitingThe Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial FibrillationDenmark
-
Yonsei UniversityRecruitingPatient With Atrial Fibrillation or High Stroke RiskKorea, Republic of
-
AstraZenecaTerminatedStroke Prevention in Patients With Atrial FibrillationSweden, Norway, Poland, United Kingdom, Finland, Denmark, United States, Czech Republic, Belgium
-
Memorial Sloan Kettering Cancer CenterWashington University School of Medicine; The Cleveland Clinic; Vanderbilt University...Active, not recruitingThoracic Surgery | Atrial Fibrillation in High Risk PatientsUnited States
-
Sohag UniversityNot yet recruitingPatients With Atrial Fibrillation Receiving Oral Anticoagulants
-
Yonsei UniversityRecruitingPatients With Atrial Fibrillation Undergoing Catheter AblationKorea, Republic of
Clinical Trials on Anticoagulation group(Apixaban group)
-
Yonsei UniversityRecruitingAtrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial FibrillationKorea, Republic of
-
University of UtahNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingKnowledge, Attitudes, Practice
-
Universidade do Vale do SapucaiPfizer; Apsen Farmaceutica S.A.; Biofarma; Dermadia; Methodos LaboratoryCompleted
-
University of Roma La SapienzaRecruitingAtrial Fibrillation | Ischemic Heart DiseaseItaly
-
University of Sao Paulo General HospitalCompletedOsteoarthritis, Knee
-
Charite University, Berlin, GermanyDepartment of Neurology, Charité - Universitätsmedizin Berlin, Germany; Department...Unknown
-
Aqua Medical Services (Pvt) LtdCompletedLumbar Disc Herniation | Spinal Disk Injury | ProtrusionPakistan
-
Cairo UniversityCompleted
-
Al-Azhar UniversityCompleted
-
Zagazig UniversityCompleted